Nevro Aktie [WKN DE: A12EPL / ISIN: US64157F1030]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Nevro Corp

11.08.24		Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
09.01.24		Nevro Expects Q4 Revenues To Grow 4%, To Lay Off 5% Of Workforce (RTTNews)
30.11.23		Nevro Announces Acquisition of Vyrsa™ Technologies (PR Newswire)
20.11.23		Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain (PR Newswire)
01.11.23		Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance (PR Newswire)
04.10.23		Nevro to Report Third Quarter 2023 Financial Results (PR Newswire)
18.09.23		New Data Show Health Economic Benefits Of Nevro's High-Frequency Spinal Cord Stimulation Therapy (RTTNews)
18.09.23		New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy (PR Newswire)
23.08.23		Nevro Announces Participation in Upcoming Investor Conferences (PR Newswire)
16.08.23		New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy (PR Newswire)
01.08.23		Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance (PR Newswire)
13.07.23		Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference (PR Newswire)
12.07.23		Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
27.06.23		Nevro to Report Second Quarter 2023 Financial Results (PR Newswire)
23.06.23		Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions (PR Newswire)
05.06.23		Nevro Names New Chief Commercial Officer (PR Newswire)
22.05.23		Nevro to Present at Jefferies Healthcare Conference (PR Newswire)
27.04.23		Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual (PR Newswire)
26.04.23		Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance (PR Newswire)
24.04.23		Nevro Announces Enrollment of First Patient in PDN Sensory Study (PR Newswire)
24.04.23		Nevro Announces Participation in Upcoming Investor Conferences (PR Newswire)
19.04.23		Nevro Names Kevin Thornal as New Chief Executive Officer and President (PR Newswire)
29.03.23		Nevro to Report First Quarter 2023 Financial Results (PR Newswire)
07.03.23		Nevro Announces U.S. Full Market Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain (PR Newswire)
23.02.23		Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series (PR Newswire)
16.02.23		Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance (PR Newswire)
01.02.23		Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference (PR Newswire)
31.01.23		Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year (PR Newswire)
19.01.23		Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results (PR Newswire)
12.01.23		Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting (PR Newswire)
09.01.23		Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance (PR Newswire)
19.12.22		Nevro to Present at 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
14.12.22		Nevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual Meeting (PR Newswire)
02.11.22		Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy (PR Newswire)
13.10.22		FDA Approves Nevro's HFX IQ Spinal Cord Stimulation System To Personalize Treatment Of Chronic Pain (RTTNews)
13.10.22		Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain (PR Newswire)
10.10.22		Nevro Comments on UnitedHealthcare Medical Coverage Policy Update (PR Newswire)
05.10.22		Nevro to Report Third Quarter 2022 Financial Results (PR Newswire)
05.10.22		Nevro :FDA Oks Manufacturing Operations In Costa Rica For Spinal Cord Stimulation Systems Production (RTTNews)
04.10.22		Nevro Announces FDA Approval of Costa Rica Manufacturing Operations (PR Newswire)
03.10.22		Nevro Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuro... (PR Newswire)
01.09.22		Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy (PR Newswire)
09.08.22		Nevro Announces Participation In Upcoming Investor Conferences (PR Newswire)
03.08.22		Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance (PR Newswire)
01.08.22		Nevro And Boston Scientific Reach $85 Mln Settlement Of Ongoing Intellectual Property Litigations (RTTNews)
01.08.22		Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations (PR Newswire)
21.07.22		Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference (PR Newswire)
06.07.22		Nevro to Report Second Quarter 2022 Financial Results (PR Newswire)
05.07.22		Newly Released Clinical Data Demonstrates Substantial Improvement in Overall Health-Related Quality of Life in Patients with Painful Diabetic Neuropathy Treated with Nevro HFX Spinal Cord Stimulat... (PR Newswire)
07.06.22		Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Wall Street-Analysten sagen Rekordwachstum voraus - diese Unternehmen werden am meisten profitieren

Solana Kurs Prognose: 1.000 US-Dollar bis Jahresende?

Diese Aktien empfehlen Experten zu kaufen

Pierer Mobility-Aktie dreht ins Minus: KTM-Mutter Pierer Mobility-Aktionäre stimmen für Kapitalerhöhung

NVIDIA auf dem Weg zu neuen Höhen? Experten sehen Potenzial im Jahr 2025

Geopolitische Schocks 2025: NATO ohne die USA und ein Atomdeal mit dem Iran als mögliche Markttreiber

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	28.01.2025 00:47
Kaufwert:	EUR
	Hinzufügen Speichern